Genetic expression of endothelial and inducible forms of nitric oxide synthase in the normal and falling human hearts  by Wei, Chi-Ming et al.
JACC February 1996 ABSTRACTS- Young Ievcstigaters Awards 3A 
and molecular markers of hyperlmpby, vantdcular and non-cardiac expres- 
sion of ET-1 mRNA and the effects of bessntan, an orally-active compatJlJve 
ETA and ETB receptor antagonist without adrenocoptor antagonism. Methods 
andResults Initially, a rat model of ventdcular hypertrophy due to continuous 
infusion of NE (600 #g/kg/h up to 7 days) by subcutaneous osmotic pumps 
was used. Male Sprague-Dawlay rats (175-200 g, n = 70) were divided into 4 
groups: 1. Sham.operated, 2. NE-infused, 3. Sham-opsrated given besentan 
(100 mg/kg/day by gavaga), 4. NE-infused given besantan. NE caused a 35- 
fold increase in ventdcular ET-I mRNA within 1 day (sham - ET-I:GAPDH 
mRNA, 0.01 ~- 0.01 at 1 day, n = 6 vs NE-  ET-I:GAPDH mRNA, 0.35 :E 
0.08, n = 8, P < 0.01), an effect not seen in lung, kidney or skeletal muscle. 
NE also caused significant increases in ventticular weight, RNA:protein, and 
expression of mRNAs for atrial natrluretio factor (ANF), beta-myosin heavy 
chain and skeletal alpha-aatin, which in adult ventricle are indicators of hy- 
pertrophy (fig. A). Bosentan blocked NE-induced hypertrophy at 5 days. In 
vitro, NE increased expression of ET-1 mRNA by cultured ventdcular my- 
ocytas and led to hypertrophy with increased ceU size, saroomedzation and 
expression of ANF mRNA, Myocyto protein content and [3H]-phenylalanine 
incorporation also increased, effects blocked by 10 #M bosantan (fig. B). 
Conclusion ET-1 plays a direct role in mediating NE-inducod hypertrophy 
wi~ 'Cross-talk' between these systems in vivoand in vitro. 
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~ Cis/Trans Regulation of Vascular Endothelial 
Growth Factor mRNA Stability by Hypoxia 
Andrew P. Levy, Nlna S. Levy, Mark A. Goldbarg. Boston University School 
of Medicine, Boston, MA 
Hypoxia has been shown to be an important stimulus for the formation of new 
blood vessels in the coronary collateral circulation in coronary artery disease. 
Vascular endothelial growth factor, a potent angiegsnie factor, is regulated by 
hypoxia in vitro and in viv,~. The major control point for the hypoxic induction of 
the VEGFgane is the regulat;,'~n ofthe steady-state l vel of the mRNA which is 
determined by the relative rates of mRNA synthesis and decay. We previously 
demonstrated a discrepancy between the transcription rate and the steedy- 
state mRNA level induced by hypoxia. This lead us to examine the post- 
transcdptional regulation of VEGF expression. A~nomyctn D experiments 
revealed that hypoxia increased VEGF mRNA halHife from 43 ~ 6 minutes 
to 106 ± 9 minutes. Using an in vitro mRNA degradation assay the half-life 
of VEGF mRNA 3' untranslated region (UTR) transsdpts were also found 
to be increased when incubated with hypoxic versus normoxie extracts. 
Both cis.reguiatory elements involved in VEGF mRNA degradation under 
normoxlo conditions and in increased stabilization under hypoxio conditions 
were mapped using this degradation assay. Hypsxia.induced proteins were 
identified by RNA alactremobility shift assay that bound to the sequences 
in the VEGF 3' UTR which mediated increased stability in the degradation 
assay. The binding site of one of these proteins was localized in the VEGF 3' 
UTR within 20 bases of the nonamerio sequent'e, UUAUUUAUU, previously 
shown to mediate the rapid degradation of multiple cytokine and oncogene 
mRNAs. This suggests a novel mechanism whereby these hypoxia-inducible 
proteins tabiliZe VEGF mRNA by interfering with the nonamedc site binding 
to its cognate binding protein(s). Furthermore, ganistsln, a tyrosine kinase 
inhibitor which was recently shown to inhibit he hypoxic induction of VEGF 
mRNA through its action on sre, blocked the hypoxia-induced stebilization 
of VEGF 3' UTR transcripts and inhibited hypoxia-induced protein binding to 
the VEGF 3' UTR while having no effect on the hypoxla-inducad increase 
in transcription of the VEGF gane. This suggests a signal cascade throUgh 
srrJraf and MAP kinase that has as its terminal event a protein that binds 
to VEGF mRNA and mediates its hypoxic stsbllization. An understanding of 
the molecular basis of the regulation of VEGF by hypoxia forms the essential 
groundwork for the rational design of pharmacological gents to increase 
VEGF expression and thereby augment neovsscularization i regions of 
ischemio myo(~u'dlum. 
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~ A  Novel Atherogenle Activity of  Upoprotein(a): 
Induction of Monooyte Chemotactle Activity in 
Human Umbilical Vein Endothelial Cells 
Michael Pann, Xiaoxia Zhang, Mark B. Taubman, Peter C. Haq~el. Mount 
Sinai School of Medicine, New York, IVY 
Elevated levels of lipoprotein(a) (Lp(a)) are associated with increased dsk 
of cardiovascular mortality and molt:)idity. Recruitment of monocytes to the 
blood vessal wall is an early event in the pethogenasis of atherosclerosis. 
We now report that Lp{a) induces the secretion of monocyte chemataCtic 
activity (MCA) by human umbilical vein endothelial cells (HUVEC). MCA was 
assayed using a modified Boyden Chamber. Minimal MCA was produced 
by HUVEC incubated in ssrum-free medium. Lp(a) induced MCA in HUVEC 
beginning at 30 rain and peaking at 2-3 hr. Peak levels were ~:80% of those 
seen with fomat-leu-phe, a potent monocyte chemoattractar¢ The induction 
of MCA was concentration dependent, with maximum MCA seen at 100 
p.g/ml of Lp(a). LDL from the same donor failed to induce MCA. In addCdon, 
Lp(a) had no direct chemotactic activity for monocytas. Polymyxin B failed to 
inhibit he stimulatory effect of Lp(a), suggesting that lipopolysaccharide was 
not the asth'e agent. Checkerboa¢l analysis documented that the activity 
presents in Lp{a)-cund~oned medium was pdmadly chemataclic rather than 
chemoldnetic. ConcOmitant Vaelment of HUVEC with Lp{a) and either 10 
p.M actinomycin D or cydoheximide completely inhibited the secretion of 
MCA into the culture medium, indicating that protein and RNA synthesis 
were required. It has been previously shown that oxidized LDL induces 
monocyte chemotanti¢ protein-1 (MCP-1) mRNA and activity in human aortic 
endothelial cells. In the currant study, Northem blot analysis showed that 
Lp(a) did not induce MCP-1 mRNA in HUVEC, indicating that Lp(a) may 
induce a chemoatlractant other than MCP-1. These studies suggest that 
Lp(a) may be involved in the recruibnent of monocytas to the vessel wall and 
provide a novel mechanism for the participation of Lp(a) in the atheroganic 
process. 
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~ Genetic Expression of Endothelial and Inducible 
Forms of Nitric Oxide Synthase in the Normal and 
Failing Human Hearts 
ChiMing Wei, Sh|-Wen Jiang, Richard C. Da]y, Christopher G. 
A. McGregor. Mayz) Clinic, Rochester, MN 
Niffic oxide (NO) is a potent endothelium-dedved relaxing factor which also 
may modulate cardiomyocyts inotropism and growth via increasing the cGMP 
level. While both the endothelial nitric oxide synthase (eNOS) and inducible 
nitric oxide synthase (iNOS) Isoforms have been detected in non-human 
mammalian tissues, expression and localization of the eNOS and iNOS in 
the normal and falling human heart am poorly defined. The present study 
was designed to investigate the eNOS and iNOS in human cardiac tissues 
in the presence and absence of congestive heart failure (CHF). Normal and 
falling atrial tissue were obtained from twelve cardiac donom and twelve end- 
stage heart failure patients undergoing cardiac b-ansplantation, eNOS and 
iNOS ~ion  and localization were inveslJgated utilizing Northern blot 
analysis, in situ hybridization and immunohiatochemisby. Norihem blot anal- 
ysis and in situ hybridization demonstrated similar levels of the eNOS and 
iNOS mRNA am present in cardiomyocytes from normal and falling hearts. 
Positive immunohistochemical staining was observed within the cytoplasm of 
cardiomyocytas. No significant different eNOS and iNOS immunore~es  
between normal and falling human myocardium were detected. The present 
studies demonstrated for the first time the genetic expression and d~tzi- 
bUtion of eNOS and iNOS in the normal and falling human hearts. These 
studies suggest that the NOS mediated paracdne and autocdne pa~way 
may sontinue to control the myocardial funstion in the failing human healts. 
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